Oramed Pharmaceuticals バランスシートの健全性
財務の健全性 基準チェック /66
Oramed Pharmaceuticalsの総株主資本は$155.5M 、総負債は$0.0で、負債比率は0%となります。総資産と総負債はそれぞれ$165.1Mと$9.6Mです。
主要情報
0%
負債資本比率
US$0
負債
| インタレスト・カバレッジ・レシオ | n/a |
| 現金 | US$142.30m |
| エクイティ | US$155.52m |
| 負債合計 | US$9.56m |
| 総資産 | US$165.08m |
財務の健全性に関する最新情報
Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Aug 24
Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
May 03Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Dec 22Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?
Jun 12Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Feb 23Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Nov 02Recent updates
Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Aug 24Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
May 03Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Dec 22Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality
Sep 21Oramed to hand Korean rights for insulin capsule
Sep 09Oramed to report early-stage trial data for oral COVID-19 shot in 3Q
Jul 07Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?
Jun 12Oramed And Oral Insulin: Can This Small Company Really Do It?
Apr 14Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Feb 23Oramed And The Hurdles Of Developing Oral Insulin
Dec 23Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Nov 02Oramed: Prospects Still Remain Despite Merck-Ridgeback's Progress
Oct 04We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation
Aug 24Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
Jul 21Oramed reaches 50% enrollment in late-stage oral insulin study
Jun 08Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
Apr 06財務状況分析
短期負債: ORMPの 短期資産 ( $142.8M ) が 短期負債 ( $5.3M ) を超えています。
長期負債: ORMPの短期資産 ( $142.8M ) が 長期負債 ( $4.3M ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: ORMPは負債がありません。
負債の削減: ORMP負債比率が0.2%であった 5 年前と比べて負債がありません。
債務返済能力: ORMPには負債がないため、営業キャッシュフロー でカバーする必要はありません。
インタレストカバレッジ: ORMPには負債がないため、利息支払い の負担は問題になりません。